Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Geoffrey R. Connors MD, FACP Associate Editor

Virginia A. Brady MD Associate Editor

Shyoko Honiden MD, MSc Editor-in-Chief

See All Experts

Published in Respiratory Medicine

Journal Scan / Research · August 10, 2024

Lipid Intensive Drug Therapy for Patients With Sepsis

Critical Care Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

Critical Care Medicine

The Lipid Intensive Drug Therapy for Sepsis Phase II Pilot Clinical Trial

Crit. Care Med. 2024 Aug 01;52(8)1183-1193, FW Guirgis, LP Black, M Henson, A Bertrand, E DeVos, J Ferreira, H Gao, SS Wu, C Leeuwenburgh, L Moldawer, F Moore, ST Reddy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Lipid Intensive Drug Therapy for Patients With Sepsis

Additional Info

The Lipid Intensive Drug Therapy for Sepsis Phase II Pilot Clinical Trial

Further Reading

Final Note From the Respiratory Medicine Editors

Prognostic Significance of Right Atrial Volume and Interval Changes in Patients With Idiopathic Pulmonary Arterial Hypertension

Economic Value of Improving Sensitivity Bronchoscopy for Malignancy Diagnosis in Peripheral Pulmonary Lesions

Biomarker-Guided Antibiotic Duration in Patients Hospitalized With Suspected Sepsis

High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure

Global, Regional, and National Mortality Burden Attributable to Air Pollution From Landscape Fires

Benralizumab in the Treatment of Patients With Eosinophilic Exacerbations of Asthma and COPD

Efficacy and Safety of Adjunctive Midodrine Therapy for Vasopressor-Dependent Shock in the ICU

Prevalence of Chronic Airflow Limitation, Emphysema, and Impaired Diffusing Capacity in Relation to Smoking Habits in Middle-Aged Populations

Feasibility of Antibiotic Allergy De-Labeling in the ICU

Impact of Dyspnea on Quality of Life in Adults With Respiratory Symptoms Without a Defined Diagnosis

Recently Updated